Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Rajendra Tangallapally und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS1000, Memphis, Tennessee 38105, Uni…. Hauptthemen laut MEDLINE: Phosphotransferases (Alcohol Group Acceptor), Pyridazines, Brain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, American Lebanese Syrian Associated Charities.
Abstract (Originalsprache)
Conversion of pantothenate to phosphopantothenate in humans is the first dedicated step in the coenzyme A (CoA) biosynthesis pathway and is mediated by four isoforms of pantothenate kinase. These enzymes are allosterically regulated by acyl-CoA levels, which control the rate of CoA biosynthesis. Small molecule activators of the PANK enzymes that overcome feedback suppression increase CoA levels in cultured cells and animals and have shown great potential for the treatment of pantothenate kinase-associated neurodegeneration and propionic acidemias. In this study, we detail the further optimization of PANK pyridazine activators using structure-guided design and focus on the cellular CoA activation potential, metabolic stability, and solubility as the primary drivers of the structure-activity relationship. These studies led to the prioritization of three late-stage preclinical lead PANK modulators with improved pharmacokinetic profiles and the ability to substantially increase brain CoA levels. Compound 22 (BBP-671) eventually advanced into clinical testing for the treatment of PKAN and propionic acidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS1000, Memphis, Tennessee 38105, United States.
- Department of Host Microbe Interactions, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS1000, Memphis, Tennessee 38105, United States.
- Department of Structural Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS1000, Memphis, Tennessee 38105, United States.
ORCID-Profile: Mi-Kyung Yun, Richard E Lee
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- American Lebanese Syrian Associated Charities
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Tangallapally, R., Subramanian, C., Yun, M. K., Edwards, A., Sharma, L. K., Yang, L., Creed, K., Wang, J., Jackowski, S., Rock, C. O., White, S. W., & Lee, R. E. (2024). Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01211
Vancouver
Tangallapally R, Subramanian C, Yun MK, Edwards A, Sharma LK, Yang L, et al. Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01211
BibTeX
@article{Tangallapally2024,
author = {Tangallapally, Rajendra and Subramanian, Chitra and Yun, Mi-Kyung and Edwards, Anne and Sharma, Lalit Kumar and Yang, Lei and Creed, Katie and Wang, Jina and Jackowski, Suzanne and Rock, Charles O and White, Stephen W and Lee, Richard E},
title = {Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01211}
}
EUVIMED